The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib

Frontiers in Endocrinology

Endocrinology

Liqin Pan¹  Huijuan Feng¹  Jiaxin Luo¹  Pan Chen¹  Xiaoli Xiong¹  Wei Ouyang¹  Yuanna Ling¹  Quanliang Zou¹  Man Long² 

[1] Department of Nuclear Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China;Department of Ultrasound Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China;

关键词: differentiated thyroid cancer;    sorafenib;    radioactive iodine refractory;    real-world clinical study;    efficacy and safety;   

DOI  :  10.3389/fendo.2023.1200932

 received in 2023-04-05, accepted in 2023-06-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundSorafenib included in Chinese medical insurance is the earliest targeted drug for radioactive iodine refractory differentiated thyroid cancer (RR-DTC). This study is to further demonstrate the clinical efficacy and safety of sorafenib used in Zhujiang Hospital of Southern Medical University.MethodsRR-DTC patients treated at our Department of Nuclear Medicine in Zhujiang Hospital of Southern Medical University (October 2017–May 2020) were retrospectively analyzed. Treatment effects, progression-free survival (PFS), and adverse effects (AEs) during medication were evaluated.ResultsOf the 31 patients included, 26 patients were evaluated for efficacy with a median follow-up time of 17.5 months (4.0–51.0 months). The disease control rate (DCR) was 57.7% (n = 15) and the objective response rate (ORR) was 26.9% (n = 7). Most patients with disease control had thyroglobulin decreases of more than 60% (p = 0.004), ORRs were favorable in patients with lung metastasis and lung-only metastasis (p = 0.010 and 0.001, respectively). The PFS of the 26 patients analyzed was 16.5 months (95%CI: 14.41 –23.90 months). In the subgroup analysis, female, patients with lung-only metastasis, hand-foot skin syndrome (HFS), and thyroglobulin response ≥ 60% observed longer PFS (p = 0.038, 0.045, 0.035, and 0.000, respectively), while patients with bone metastasis had lower PFS (p = 0.035). The most common toxicity profile was HFS (93.5%), followed by diarrhea (83.9%), alopecia (74.2%). All the side effects were mainly grade 1–2. Grade 3–4 adverse reactions were more common in diarrhea and HFS.ConclusionsSorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The AEs of sorafenib were generally mild, and the main AE was HFS.

【 授权许可】

Unknown   
Copyright © 2023 Ling, Xiong, Luo, Zou, Chen, Pan, Long, Feng and Ouyang